Published ahead of print on June 23, 2005, doi:10.1164/rccm.200501-122OC
© 2005 American Thoracic Society doi: 10.1164/rccm.200501-122OC Extended Haplotype in the Tumor Necrosis Factor Gene Cluster Is Associated with Asthma and Asthma-related PhenotypesChanning Laboratory, Brigham and Women's Hospital, Harvard Medical School; Department of Anesthesia, Children's Hospital and Harvard Medical School; and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts Correspondence and requests for reprints should be addressed to Adrienne Randolph, M.D., M.Sc., Children's Hospital, MICU, FA-108, 300 Longwood Avenue, Boston, MA 02115. E-mail: adrienne.randolph{at}childrens.harvard.edu
Rationale: Tumor necrosis factor is a proinflammatory cytokine found in increased concentrations in asthmatic airways. The TNF- (TNF) and lymphotoxin- (LTA) genes belong to the TNF gene superfamily located within the human major histocompatibility complex on chromosome 6p in a region repeatedly linked to asthma. The TNF position 308 and LTA NcoI polymorphisms are believed to influence TNF transcription and secretion, respectively. Objectives: This study sought to determine whether polymorphisms in TNF or LTA, or in TNF-LTA haplotypes, are associated with asthma and asthma phenotypes. Methods: We genotyped the TNF 308 and LTA NcoI polymorphisms, and two other haplotype-tagging polymorphisms in the TNF and LTA genes, in 708 children with mild to moderate asthma enrolled in the Childhood Asthma Management Program and in their parents. Using an extension of the family-based association tests in the PBAT program, each polymorphism was tested for association with asthma, age at onset of asthma, and time series data on baseline FEV1 % predicted, postbronchodilator FEV1 % predicted, body mass index, and log of PC20. Measurements and Main Results: Although no associations were found for the individual single-nucleotide polymorphisms, the haplotype analysis found the LTA NcoI_G/LTA 4371T/TNF 308G/TNF 1078G haplotype to be associated with asthma and with all five phenotype groups. Conclusions: We conclude that it is unlikely that the TNF 308 or LTA NcoI polymorphisms influence asthma susceptibility individually, but that this haplotype of variants may be functional or may be in linkage disequilibrium with other functional single-nucleotide polymorphisms.
Key Words: asthma haplotypes lymphotoxin-
Tumor necrosis factor is a proinflammatory cytokine that is found in increased concentrations in asthmatic airways. The TNF-
Conflicting findings in previous studies could be explained by the different populations studied, by population stratification, or by small sample sizes in case-control study designs. The TNF 308 and LTA NcoI polymorphisms are in strong linkage disequilibrium (5, 19). Moffatt and colleagues (16) have advocated that haplotypes created by the TNF 308 and LTA NcoI polymorphisms and surrounding innate immunity genes in the major histocompatibility complex may explain the conflicting results. A Japanese study showed significant transmission disequilibrium with haplotypes in the TNF genes (26). Using a family-based design to control for population stratification in a large cohort of children with mild to moderate asthma, we tested the TNF 308 and LTA NcoI polymorphisms, and extended TNF/LTA haplotypes for association with asthma. Some of the results of these studies have been previously reported in the form of an abstract (27).
Population The Childhood Asthma Management Program (CAMP) was a multicenter, randomized, double-masked, placebo-controlled clinical trial evaluating the long-term effects of inhaled antiinflammatory medications in children with mild to moderate asthma (28). The diagnosis of asthma was based on methacholine hyperreactivity (PC20 no greater than 12.5 mg/ml) and the meeting of one or more of the following criteria for at least 6 months in the year before recruitment: (1) asthma symptoms two times or more per week; (2) at least two uses per week of an inhaled bronchodilator; and (3) daily asthma medication. See the online supplement for a description of spirometry, including methacholine challenge (29), and other testing methods. Of the 1,041 children participating in the original CAMP study (29), DNA samples were obtained from 968 participating children and 1,518 of their parents. Complete family trios were available for 652 nuclear families that included 708 children. Some families had multiple children with asthma (49 families had two children and two families had three children). The characteristics of these children are shown in Table 2.
Choice of SNPs and Molecular Methods Choice of SNPs and SNP locations are described in detail in the online supplement, including representation of the SNPs reported as being significantly overtransmitted to Japanese individuals with atopic asthma (26). Briefly, haplotypes were identified with the PHASE program (30) and this output was analyzed by the BEST program (31) to identify haplotype-tagging SNPs. As shown in Table 3, the four SNPs chosen for genotyping should have been able to distinguish all of the common (more than 7%) haplotypes identified in Europeans. SNP genotyping was performed with the SEQUENOM system (see the online supplement for a detailed description).
Statistical Analysis The PedCheck program was used to assess the genotype data for pedigree errors (32). Hardy-Weinberg equilibrium was tested in the parental data for each locus, using the 2 goodness of fit test in SAS (version 8.1; SAS Institute, Cary, NC). The primary analysis was for association of individual SNPs and haplotypes with asthma, applying the PBAT (33) program to the entire sample for the SNP analysis and to white individuals for the haplotype analysis. In the PBAT program the recessive model was used because that model had optimal power, as has been shown in previous studies (34, 35). The secondary analysis was to test each individual SNP/haplotype for association with a time series of asthma-related quantitative phenotypes, using the PBAT program (36). The time series data were obtained during multiple visits (before, at, and after study entry) to children in the CAMP population (see the online supplement for details). We tested the age at onset of asthma and the following four-time series: body mass index (BMI), logarithm of the provocative concentration of methacholine causing a 20% fall in FEV1 from baseline (LNPC20), baseline FEV1 % predicted (Pre-FEV), and postbronchodilator FEV1 % predicted (Pos-FEV). The time series data were tested with the FBAT-PC statistic for repeated measurements (36) and the time-to-onset data were tested with FBAT-LOGRANK (37). Both tests are available in PBAT for SNP and haplotype analysis. Pairwise linkage disequilibrium between each pair of SNP loci was evaluated by a maximum likelihood method to infer phases for dual heterozygotes, expressed as r2.
Genotyping Results and Haplotype Evaluation Genotypes for families with pedigree check errors were set to zero. The number of PedCheck errors for each SNP were as follows: LTA NcoI (23), LTA 4371 (9), TNF 308 (3), and TNF 1078 (3). Genotyping success rates were 97% or greater for each SNP. Hardy-Weinberg equilibrium was confirmed for all loci in the parents (all p values were greater than 0.1). There was significant linkage disequilibrium between the TNF 308 and LTA NcoI SNPs (r2 = 0.424). The LTA NcoI SNP and the LTA 4371 SNP had an r2 value of 0.172, and the TNF 282 SNP and LTA 4371 SNP had an r2 value of 0.083. The r2 values for all other SNP pairs were less than 0.04. There were five four-SNP haplotypes represented in the sample at 5% or greater frequency in any ethnic group. The common haplotypes represented in the sample were the same as those with 5% or greater frequency reported in Table 3 for the Centre d'Etude du Polymorphisme Humain European sample.
Family-based Association Analysis of the TNF SNPs and Haplotypes with Asthma
We restricted the extended haplotype analysis to white subjects. As shown in Table 5, there was an increase in transmission of the LTA NcoI_G/LTA 4371T/TNF 308G/TNF 1078G (GTGG) haplotype, using the recessive model (GTGG = 167 vs. other haplotypes = 146; relative risk, 2/0 copies GTGG = 3.1 and 1/0 copy GTGG = 2.75, p = 0.05). The p values shown in Table 5 are corrected for multiple comparisons. Table 5 also shows the results of the haplotype analysis for the GTGG haplotype for asthma-related phenotypes. The GTGG haplotype was associated with later age of onset of asthma based on the Kaplan-Meier plot (Figure 2). The GTGG haplotype was also associated with BMI, LNPC20, Pre-FEV, and Pos-FEV, using the time-series phenotype data.
Our data indicate that the TNF 308 and LTA NcoI polymorphisms do not influence asthma susceptibility individually, but that an extended haplotype in the TNF and LTA genes is associated with asthma susceptibility and with multiple common asthma phenotypes. In contrast to seven published case-control studies that showed an increased frequency of the TNF 308A allele in individuals with asthma (39), we instead found a strong trend toward an increased frequency of transmission from parents of the G allele to their child with asthma, consistent with other investigators in two case-control studies (19, 20). The TNF and LTA genes are located in the major histocompatibility complex on chromosome 6 between many innate immunity genes (see Figure 1). We believe that previous linkage with asthma in this region may be explained by extended haplotypes across the TNF and LTA genes. Our study has many strengths. We used a family-based genetic study design including a large number of parentchild trios. Our population included more subjects with asthma than have been previously enrolled in other published studies evaluating SNPs in TNF and LTA genes (see Table 1). All children had mild to moderate asthma and extensive asthma phenotype data had been collected longitudinally (29). Genotyping success rates were high and we were able to infer haplotypes from family-based data at a high rate. Our study is limited by the number of SNPs that were genotyped. Because our population was largely white, we chose SNPs to replicate findings in published reports and chose additional SNPs to ensure good representation of common haplotypes. We cannot rule out the possibility that linkage disequilibrium between polymorphisms in the asthmatic population may be different from those in the nonasthmatic population. This is unlikely, however, because our four-SNP haplotype results are consistent with those reported for the nonasthmatic European Centre d'Etude du Polymorphisme Humain sample. With the four-haplotypetagging SNPs we chose, we were able to test the majority of common haplotypes across the TNF and LTA genes for association with asthma. Noguchi and colleagues (26) reported an association between a TNF polymorphism and asthma susceptibility in a population of Japanese children with atopic asthma in 144 families. They reported increased transmission of the C allele of the TNF 857C/T SNP to children with asthma in 54 informative families. Further evaluation of haplotypes showed significantly increased transmission of the TNF 1031T/857C (our SNPs LTA 4371T/TNF 1078G) haplotype in 74 informative families. Although we substituted the TNF 1078 SNP for their SNP labeled 857, these two SNPs are reported to be in 100% linkage disequilibrium in nonasthmatic white individuals. The TNF 308 SNP is not found in the Japanese population (26). Our results do not contradict the finding of Noguchi and colleagues (26), but our haplotypes are more extended. The TNF distal promoter haplotype they reported is broken into subhaplotypes in our mostly white sample, and we had a much larger population of individuals with asthma with many more informative families. Whether the TNF 308 locus modulates the levels of tumor necrosis factor transcription is controversial. To resolve this controversy, Knight and colleagues (38) used chromatin immunoprecipitation and mass spectrometry (haplo-CHIP analysis) to identify differential proteinDNA binding in vivo associated with allelic variants of the TNF and LTA genes. Using Epstein-Barr virustransformed B-cell lines, they evaluated RNA polymerase II loading and tumor necrosis factor mRNA expression. Their haplo-CHIP analysis of the 308 TNF polymorphism did not find differential expression of tumor necrosis factor by the two alleles of the SNP. They then extended their haplotypes to include SNPs across the LTA gene. They identified only three major haplotypes across these two genes. Two of the haplotypes had increased transmission of tumor necrosis factor (TNF 1031T_TNF308A_LTA NcoIG and TNF 1031C_TNF 308G _LTA NcoIA) in comparison with the third haplotype (TNF 1031T_TNF 308G_LTA NcoIA). These haplotypes represent the following respective haplotypes in Table 3: haplotype 4, haplotype 2 or 6, and haplotype 1 or 5. Haplotype 3 (Table 3), which we found to be positively associated with asthma, was not represented in their analysis. Extrapolation from the study by Knight and colleagues (38) is limited because three common haplotypes found in asthmatic and nonasthmatic subjects are missing from their analysis. However, it is clear from their study that the TNF 308 SNP does not upregulate tumor necrosis factor levels and is not likely to be the important SNP as previously hypothesized. We were not able to test whether haplotype 3 (Table 3) had a regulatory effect on tumor necrosis factor levels. In a large population of children with mild to moderate asthma, we have shown that the TNF 308 and LTA NcoI loci are not associated with asthma susceptibility or asthma phenotypes. Our results are consistent with the majority of other case-control and family-based studies shown in Table 1 that failed to find an association between asthma and these two loci. One haplotype across the TNF and LTA genes was found to be associated with asthma susceptibility and with asthma phenotypes in our cohort. Future studies of the association of polymorphisms in the TNF and LTA genes should evaluate extended haplotypes across the TNF and LTA genes and across other nearby genes in the major histocompatibility complex (5).
The authors thank all families for their enthusiastic participation in the CAMP Genetics Ancillary Study, supported by the National Heart, Lung, and Blood Institute (NO1-HR-16049). The authors also acknowledge the CAMP investigators and research team, supported by the NHLBI, for collection of CAMP Genetic Ancillary Study data. All work on data from the CAMP Genetics Ancillary Study was conducted at the Channing Laboratory, Brigham and Women's Hospital under appropriate CAMP policies and human subject protections.
Supported by National Institutes of Health (NIH) grants K23HL04278, U01 HL66795, PO1 HL67664, and P50 HL67664, and by MedImmune, Inc. A.G.R. is supported by NIH NHLBI K23 award HL04278. This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Conflict of Interest Statement: A.G.R. received an unrestricted $10,000 education grant from MedImmune, Inc., to pay for genotyping costs. C.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E.K.S. received grant support and honoraria from GlaxoSmithKline for a study of chronic obstructive pulmonary disease (COPD) genetics. He also received a $500 speaker fee from Wyeth for a talk on COPD genetics. R.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.T.W. received a grant for $900,065, Asthma Policy Modeling Study, from AstraZeneca from 1997 to 2003. He has been a coinvestigator on a grant from Boehringer-Ingelheim to investigate a COPD natural history model that began in 2003. He has received no funds for his involvement in this project. He has been an advisor to the TENOR Study for Genentech and has received $5,000 for 20032004. He received a grant from GlaxoWellcome for $500,000 for genomic equipment from 2000 to 2003. He was a consultant for Roche Pharmaceuticals in 2000 and received no financial remuneration for this consultancy. Received in original form January 26, 2005; accepted in final form June 5, 2005
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||